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We describe a case of a young woman who had methicillin-resistant Staphylococcus aureus USA300 clone
(MRSA-USA300)-associated Lemierre’s syndrome and secondary necrotizing pneumonia and cerebral
infarcts. We also review 11 cases of S. aureus-associated Lemierre’s syndrome reported in the literature
from 1965 to 2010. Recognition of S. aureus as an emergent cause of Lemierre’s syndrome informs the
initial empirical antibiotic choice for this life-threatening condition and may positively impact patient
outcomes.
CASE REPORT
A 22-year-old previously healthy Caucasian woman pre-
sented with a 2-week history of right neck pain and low-grade
fever and a 1-week history of sore throat and nonproductive
cough. She underwent a limited evaluation at the emergency
department of hospital A, which led to treatment of symptoms
with analgesics and discharge to her home. After her neck pain
and fevers progressed within a week, she underwent reevalu-
ation and admission to hospital A. A chest X-ray revealed
nodular infiltrates in both lungs. The treating physicians or-
dered the initiation of empirical treatment with ceftriaxone
after obtaining anaerobic and aerobic blood cultures. Soon
after, the patient developed confusion; a computed tomogra-
phy (CT) scan of the brain showed cerebral infarcts. She also
received supplemental oxygen therapy for respiratory hypox-
emia and distress. She underwent transfer to Barnes-Jewish
Hospital (BJH). Upon arrival at BJH, she complained of
throat and neck pain, cough, and shortness of breath. Vital
signs revealed tachypnea and tachycardia. She had difficulty
speaking due to inspiratory stridor and was unable to open her
mouth completely due to pain. A physical exam revealed bi-
lateral periorbital and facial edema, bilateral anterior cervical
tenderness, and coarse breath sounds bilaterally. She also ap-
peared mildly confused. The rest of the physical exam was
unremarkable. Laboratory analysis revealed leukocytosis, ane-
mia, and thrombocytopenia (white blood cell count of 15,000
[15.0K]/mm3 [reference range, 3.8K to 9.8K/mm3], with 95%
neutrophil predominance, hemoglobin level of 11.0 g/dl [ref-
erence, 12.1 to 15.1 g/dl], and platelet level of 72K/mm3 [ref-
erence, 140K to 440K/mm3]). Basic metabolic panel and liver
function tests were unremarkable. The treating physician ad-
mitted the patient to the intensive care unit (ICU). The ICU
team empirically started the patient on intravenous vancomy-
cin, ceftriaxone, and clindamycin. Soon after admission to the
ICU, the team intubated the patient and initiated mechanical
ventilation due to respiratory distress. Arterial blood gas anal-
ysis postintubation revealed a pH of 7.5, partial CO2 pressure
(pCO2) of 31 mm Hg, and partial oxygen pressure (pO2) of 135
mm Hg. Serum monospot and rapid HIV tests had negative
results. Cerebrospinal fluid analysis revealed 314 nucleated
cells that had 65% neutrophils, 15% lymphocytes, and 6%
monocytes, a glucose level of 59 mg/dl (60% of serum glucose),
and a protein level of 46 mg/dl. Blood cultures from hospital A
grew Staphylococcus aureus resistant to erythromycin and ox-
acillin and susceptible to clindamycin, doxycycline, linezolid,
trimethoprim-sulfamethoxazole, and vancomycin. Blood and
cerebrospinal fluid cultures from BJH also grew S. aureus, with
identical drug susceptibility patterns. CT scans of the neck and
chest revealed thrombi in the right and left internal jugular
vein and multiple septic emboli in the lungs. Magnetic reso-
nance imaging (MRI) of the head showed multiple cerebral
infarcts. A transesophageal echocardiogram performed on the
same day as vancomycin initiation did not show any valvular
vegetations. The clinical scenario led to the diagnosis of septic
thrombophlebitis of the bilateral internal jugular veins, or Le-
mierre’s syndrome, with septic emboli to the lungs and brain,
secondary to methicillin-resistant S. aureus (MRSA). The pa-
tient’s blood cultures turned negative after 48 h of vancomycin
and clindamycin therapy. Clindamycin was discontinued after 7
days. Her hospitalization was complicated by acute respiratory
distress syndrome (ARDS) and necrotizing pneumonia with
subsequent development of bilateral pneumothoraces and
bronchopleural fistulae. Her respiratory status improved grad-
ually over the course of 1 month, and ventilatory support was
eventually discontinued. She completed a 6-week course of
trough-level-adjusted intravenous vancomycin therapy. Molec-
ular typing of the MRSA isolate from her blood (16) revealed
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that it contained staphylococcal chromosomal cassette mec
type IV (SCCmecIV) and clustered to multilocus sequence
type 8 (MLS type 8), consistent with MRSA-USA300.
Discussion. Here we describe a case of a young woman who
had methicillin-resistant Staphylococcus aureus USA300 clone
(MRSA-USA300)-associated Lemierre’s syndrome and sec-
ondary necrotizing pneumonia and cerebral infarcts. Failure to
initially recognize the illness resulted in a delay in appro-
priate antibiotic administration and likely increased morbid-
ity. Awareness of the clinical presentation of Lemierre’s syn-
drome (fever and neck pain preceded by tonsillopharyngitis)
(7) and of its causative agents will lead to timely and appro-
priate antibiotic administration and better outcomes. Fusobac-
terium necrophorum, an anaerobic Gram-negative bacterium,
causes two-thirds of cases of Lemierre’s syndrome; other caus-
ative organisms include Streptococcus viridans, Bacteroides clos-
tridiiformis, Peptostreptococcus magnus, Fusobacterium navi-
forme, and Eikinella corrodens (20). Clinicians typically use
beta-lactams, clindamycin, and third-generation cephalospo-
rins to treat infection with these organisms. Reports have not
frequently described S. aureus as a cause of Lemierre’s syn-
drome (7). Without awareness of MRSA as a causative agent,
clinicians may delay appropriate antibiotic coverage.
A PubMed search (http://www.ncbi.nlm.nih.gov/sites/entrez?db
pubmed) from 1965 to the present for septic internal jugular
vein thrombosis caused by S. aureus, excluding cases secondary
to intravenous catheters, revealed a total of 11 cases reported
in the literature (Table 1). All of these cases were published
after 2002. The articles describe a higher frequency of unilat-
eral internal jugular vein thrombosis than of bilateral involve-
ment. For all cases, metastatic spread to the lungs is reported;
few involved the central nervous system. One elderly patient
died. Only a single case, a 7-month-old infant who presented
with a retropharyngeal abscess and left internal jugular vein
thrombosis, had the causative S. aureus strain conclusively
typed as MRSA-USA300 (15). To the best of our knowledge,
we describe the first reported case of Lemierre’s syndrome in
an adult secondary to S. aureus conclusively typed as MRSA-
USA300.
MRSA-USA300 has emerged as a cause of skin and soft
tissue infections, prosthetic joint infections, and necrotizing
pneumonia over the last decade (14, 21, 22). The reasons for its
emergence remain unclear, but they likely relate to virulence
factors unique to its biology that enable it to spread from
person to person in the community and cause severe invasive
disease in susceptible hosts (26). Among MRSA isolates re-
covered from patients in the United States, USA300 and
USA400 were initially found among patients with no known
hospital contact and therefore referred to as community asso-
ciated. However, MRSA-USA300 has since been described as
a cause of nosocomial infections (32), indicating spread of the
organism to include health care settings. MRSA-USA300 as
determined by pulsed-field gel electrophoresis (PFGE) corre-
sponds to S. aureus MLS type 8 as determined by housekeeping
gene sequencing or repetitive sequence PCR profiling and
contains SCCmecIV (25). This clone is more likely than other
types of S. aureus to be susceptible to ciprofloxacin, clindamy-
cin, gentamicin, and trimethoprim-sulfamethoxazole (28).
The S. aureus isolate identified in this case caused a severe
and unusual clinical syndrome. Delay in the institution of ap-
propriate antibiotic therapy and other unidentified contribut-
ing factors could have accounted for progression of the infec-
tion. The young woman did not have any obvious reasons for
immunocompromise (she was young and previously healthy; an
HIV test was negative), but she was obviously susceptible to
severe S. aureus infection. Currently unidentified host risk fac-
tors, perhaps defects in innate or adaptive immunity, could
have accounted for an increased susceptibility to infection.
TABLE 1. Cases of Staphylococcus aureus Lemierre’s syndrome





Hoehn et al. (15) 7 mo MRSA-USA300 Left Septic pulmonary emboli, empyema, pneumothorax,
hemorrhagic pericardial effusion
Enoxaparin, i.v. heparin Recovered
Kadhiravan et al. (18) 16 yr MRSA Bilateral Septic pulmonary emboli, cavitation, right-sided
pleural effusion, hemoptysis
None Recovered
Puymirat et al. (29) 22 yr MSSA Right Multiple pulmonary nodules, cavitation, cavernous
sinus thrombosis
s.c. heparin, excision of
IJ and EJ
Recovered
Boga et al. (3) 22 yr MRSA Right Multiple small nodular lung densities, right-sided
pleural effusion
i.v. heparin Recovered
Herek et al. (13) 33 yr MRSA Right Multiple septic pulmonary emboli, necrotizing
pneumonia
None Recovered
Bilal et al. (2) 30 yr MRSA Right Bilateral cavitary lung nodules, right pleural
effusion, bilateral cavernous sinus thrombosis,
cranial nerve palsies
i.v. heparin Recovered
Ceylan et al. (5) 80 yr MSSA Right Bilateral pulmonary nodular infiltrates, bibasal
pleural effusion
None Recovered
Fong and Watson (11) 7 mo MRSA Right Septic pulmonary emboli, cervical abscess,
mastoiditis
Drainage of abscess Deceased
Bentley and Brennan (1) 8 yr MRSA Left Multiple pulmonary nodules Aspirin on discharge Recovered
Shivashankar et al. (33) 32 yr MSSA Left Bilateral pulmonary nodules, pulmonary abscesses,
cavernous sinus thrombosis; bilateral cerebellar,




Lim et al. (23) 32 yr MRSA Left Pulmonary infiltrates; bilateral infectious aneurysm






a Interventions in addition to broad-spectrum antibiotics. i.v., intravenous; s.c., subcutaneous; IJ, internal jugular; EJ, external jugular.
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Likewise, the microbe could have had unique virulence factors
that rendered it especially pathogenic; however, we did not
examine the isolate for other virulence factors since it would
not establish cause and effect in this case. Identification of a
certain virulence factor in this S. aureus isolate would not
necessarily mean that it is responsible for the clinical syn-
drome. Larger epidemiological studies that examine putative
host risk factors for S. aureus infection coupled with microbe
studies are needed to establish such associations.
Appropriate management of Lemierre’s syndrome requires
timely and appropriate antibiotic therapy. For severe MRSA
infections, treatment options include vancomycin (first line),
daptomycin, linezolid, and telavancin. Vancomycin serum trough
levels should remain between 15 and 20 g/ml for the duration
of therapy (30). Daptomycin should not be used for cases with
pulmonary involvement because it binds to lung surfactant and
is thereby sequestered (34). Linezolid should be avoided in
patients who are taking adrenergic or serotonergic medica-
tions due to its monoamine oxidase inhibitor activity (35).
Telavancin, a newly approved lipoglycopeptide, is a promis-
ing alternative, especially for MRSA with intermediate resis-
tance to vancomycin; however, telavancin is associated with a
slight increase in nephrotoxicity compared to vancomycin (31).
Combination therapy for severe MRSA infections is not supe-
rior to monotherapy and has in fact been associated with more
side effects (10). For example, the concomitant use of genta-
micin increases nephrotoxicity but only minimally improves
outcomes (8). Antimicrobials should be continued until clot
resolution, which usually occurs after 4 to 6 weeks of therapy.
The use of anticoagulation among patients with Lemierre’s
syndrome remains controversial (4). Clinicians should weigh
the risks and benefits of anticoagulation very carefully for each
case. No high-quality controlled trials exist to show the benefit
of anticoagulation. A few case reports support the use of an-
ticoagulation for septic internal jugular vein thrombosis (9, 27).
These authors hypothesize that anticoagulation prevents septic
embolization to distant sites. Other studies report harm from
anticoagulation (15, 19). Involvement of the cavernous sinus is
generally regarded as an indication for anticoagulation (9, 17).
One review found that the use of intravenous heparin, fol-
lowed by 3 months of warfarin, reduced morbidity among sur-
vivors (12).
Internal jugular vein ligation or excision is another impor-
tant consideration in the treatment of Lemierre’s syndrome.
Ligation was commonly performed in the preantibiotic age. It
is now rarely used and should be performed only in patients
who demonstrate recurrent episodes of embolization despite
treatment with antibiotics (6, 24). There are no specific data in
cases of bilateral internal jugular vein thrombosis to guide the
use of surgical ligation.
In summary, MRSA-USA300 is emerging as a cause of Le-
mierre’s syndrome in addition to typically recognized organ-
isms, such as F. necrophorum. Awareness of MRSA-USA300 as
a causative agent of Lemierre’s syndrome will guide empirical
antibiotic choice and may positively impact patient outcomes.
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